298 results on '"Geborek, Pierre"'
Search Results
2. Immune response to pneumococcal conjugate vaccine in patients with systemic vasculitis receiving standard of care therapy
3. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine
4. Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies
5. The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice
6. Antibody response to 13-valent pneumococcal conjugate vaccine is not impaired in patients with rheumatoid arthritis or primary Sjögren’s syndrome without disease modifying treatment
7. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial
8. Circulating complexes between tumour necrosis factor-alpha and etanercept predict long-term efficacy of etanercept in juvenile idiopathic arthritis
9. Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial
10. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study
11. BRIEF REPORT: Enhancement of Patient Recruitment in Rheumatoid Arthritis Clinical Trials Using a Multi-Biomarker Disease Activity Score as an Inclusion Criterion
12. Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial
13. Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial
14. Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial
15. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register
16. No association between rheumatoid arthritis, amyotrophic lateral sclerosis, and tumour necrosis factor inhibitor treatment
17. Sustained Remission in Patients With Rheumatoid Arthritis Receiving Triple Therapy Compared to Biologic Therapy: A Swedish Nationwide Register Study
18. Predictors of work disability during the first 3 years after diagnosis in a national rheumatoid arthritis inception cohort
19. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial
20. Biological vs Conventional Combination Treatment and Work Loss in Early Rheumatoid Arthritis: A Randomized Trial
21. Individualized outcome measures of daily activities are sensitive tools for evaluating hand surgery in rheumatic diseases
22. Sick leave in patients with ankylosing spondylitis before and after anti-TNF therapy: a population-based cohort study
23. In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial
24. Antibody Response Is Reduced Following Vaccination With 7-Valent Conjugate Pneumococcal Vaccine in Adult Methotrexate-Treated Patients With Established Arthritis, But Not Those Treated With Tumor Necrosis Factor Inhibitors
25. National EQ-5D tariffs and quality-adjusted life-year estimation: comparison of UK, US and Danish utilities in south Swedish rheumatoid arthritis patients
26. Predictors of response to methotrexate in early DMARD naïve rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial
27. Ten years with biologics: to whom do data on effectiveness and safety apply?
28. Decrease in sick leave among patients with rheumatoid arthritis in the first 12 months after start of treatment with tumour necrosis factor antagonists: a population-based controlled cohort study
29. Prevalence and incidence of rheumatoid arthritis in southern Sweden 2008 and their relation to prescribed biologics
30. Cancer risk in patients with rheumatoid arthritis treated with anti–tumor necrosis factor α therapies: Does the risk change with the time since start of treatment?
31. Studies of mechanisms underlying the prolonged neutrophil survival in ANCA-associated systemic vasculitis: G16
32. Identifying predictors of drug effectiveness in observational studies in rheumatoid arthritis: a challenging task
33. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists
34. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis
35. Individualized Monitoring of Drug Bioavailability and Immunogenicity in Rheumatoid Arthritis Patients Treated With the Tumor Necrosis Factor α Inhibitor Infliximab
36. The LUNDEX, a New Index of Drug Efficacy in Clinical Practice: Results of a Five-Year Observational Study of Treatment With Infliximab and Etanercept Among Rheumatoid Arthritis Patients in Southern Sweden
37. Risk and Case Characteristics of Tuberculosis in Rheumatoid Arthritis Associated With Tumor Necrosis Factor Antagonists in Sweden
38. Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis factor α blockade: comment on the article by Buch et al
39. Early changes in bone mineral density measured by digital X-ray radiogrammetry predict up to 20 years radiological outcome in rheumatoid arthritis
40. Infliximab, etanercept and leflunomide in rheumatoid arthritis. Clinical experience in southern Sweden
41. Survival on drug as a tool for evaluation of drug tolerability. Initial experience in southern Sweden of infliximab, etanercept and leflunomide in rheumatoid arthritis
42. Treatment with etanercept or infliximab improves hand function in patients with long-standing rheumatoid arthritis
43. Secular trends of sustained remission in rheumatoid arthritis, a nationwide study in Sweden
44. Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept
45. Measures and time points relevant for post-surgical follow-up in patients with inflammatory arthritis: a pilot study
46. Disease activity level, remission and response in established rheumatoid arthritis: Performance of various criteria sets in an observational cohort, treated with anti-TNF agents
47. Cartilage and bone macromolecules in knee joint synovial fluid in rheumatoid arthritis: relation to development of knee or hip joint destruction
48. Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma)
49. Hip involvement in early rheumatoid arthritis
50. Secular trends of sustained remission in rheumatoid arthritis, a nationwide study in Sweden.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.